To understand the in vivo alterations mediated by ibrutinib, we analyzed the circulating CD14+ population in peripheral blood samples of CLL patients before and after one month of treatment with ibrutinib. The gene discussed is CD14; the disease is B-cell chronic lymphocytic leukemia.